生命科学资讯

What Sanofi’s multiple sclerosis troubles could mean for the space

AbbVie pledges $100B to US production in drug pricing deal with Trump

JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year

AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations

5 questions facing biopharma in 2026

Building more sustainable cold chain packaging through innovation

Best practices for COA selection: Building a stronger foundation for clinical trials

Eikon, a high-profile startup led by Merck vets, seeks an IPO

Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal

Aurora sets out to capitalize on FDA’s new framework for bespoke drug therapies

Aktis raises $318M in 2026’s first biotech IPO

Alveus launches with $160M to advance MariTide-like obesity drug

Parabilis, chasing ‘undruggable’ targets, nabs $305M amid VC funding blitz

Diagonal banks another $125M for ‘clustering’ antibody drugs

EpiBiologics raises $107M for its protein-degrading cancer drug

Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs

GSK, Ionis claim study success for RNA-based hepatitis B drug

Arrowhead showcases early obesity data; Instil bails on PD-1/VEGF drug

5 FDA decisions to watch in the first quarter of 2026

Alumis soars as TYK2 drug hits mark in psoriasis trials